Mylan's ANDA Raises Sankyo's Blood Pressure
The lawsuit, filed in New Jersey, accuses Mylan of infringing on Daiichi Sankyo Co. Ltd.’s U.S. patent covering olmesartan medoxomil—Benicar’s active ingredient. The patent at issue is valid until 2016, according to Daiichi Sankyo.
The plaintiffs in the suit are Sankyo Company Ltd. and Daiichi Sankyo Inc.—subsidiaries of Daiichi Sankyo Co. Ltd.—based in Tokyo and New Jersey,...
To view the full article, register now.